Worth reading
55In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
17.9
% (year-on-year decline in operating income)Wording
Avoiding a definitive answer
How definitive the wording is.Results for this period
Full year1 April 2025–31 March 2026ConsolidatedJapanese GAAPNet Sales811,638¥ millionYear on year +0.5%Progress 99.0%
Operating profit32,894¥ millionYear on year -17.9%Progress 91.4%
Ordinary income28,873¥ millionYear on year -12.1%Progress 90.2%
Net income attributable to owners of the parent30,977¥ millionYear on year +22.4%Progress 98.3%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥501.26
Operating Margin4.1%
Financial position at period-end
Total assets959,154¥ million
of which net assets 521,669 ¥ millionEquity ratio 52.0%vs. prior year-end +0.8pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating+50,118
Investment-26,097
Financials-19,988
Net change+4,033
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period¥48,935 million
Segment revenueMaterial Solutions Unit ¥327,235 million, Quality of Life Solutions Unit ¥194,340 million, Health Care Solutions Unit ¥82,975 million, Nutrition Solutions Unit ¥205,977 million
Segment profitMaterial Solutions Unit ¥24,928 million, Quality of Life Solutions Unit ¥17,954 million, Health Care Solutions Unit ¥14,840 million, Nutrition Solutions Unit ¥13,712 million
Regional salesFiscal year ending March 2026 ¥447,982 million, ¥163,276 million, ¥74,469 million, ¥83,871 million, ¥42,039 million / Fiscal year ended March 2025 ¥440,431 million, ¥170,313 million, ¥77,101 million, ¥83,303 million, ¥36,051 million
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥820,000 million (YoY +1.0%)
Operating profit¥36,000 million (YoY +9.4%)
Ordinary income¥32,000 million (YoY +10.8%)
Net income¥31,500 million (YoY +1.7%)
Annual Dividend Forecast¥160 → ¥210（+31.3%）
Payout ratioFiscal year ending March 2026 31.9% / Forecast for the fiscal year ending March 2027 40.2%
Shareholder Return PolicyFor fiscal 2025 through fiscal 2027, the Company will maintain or increase dividends on the premise that it maintains financial soundness, following a progressive dividend policy. For the next fiscal year, the consolidated dividend payout ratio is expected to be approximately 40%.
Factors Behind Changes in Business Performance
Material posted lower revenue and income due to weak market conditions in Asia and weak demand in the U.S. residential and construction markets. QOL posted higher revenue but lower income due to higher raw material costs. Health Care posted higher revenue and income due to strong growth in Medical. Nutrition posted higher revenue and income due to strong performance in Supplement and improved profitability in Foods.
Disclosure regarding the going concern assumption
Not applicable.
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew 0 companies / Excluded 0 companies / Company name Not disclosed
Material subsequent eventsNot applicable.
Impairment loss¥2,404 million
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of investment securities ¥22,714 million, Subsidy Income ¥2,548 million, Gain on bargain purchase ¥273 million / Extraordinary loss Litigation-Related Costs ¥897 million, Business restructuring loss ¥701 million, Product Warranty Costs ¥2,502 million, Losses from natural disasters ¥594 million, Loss on reduction of fixed assets ¥1,248 million, Provision for special reserve for deferred gain on replacement assets ¥1,300 million, Impairment Losses ¥2,404 million
Depreciation and amortization¥47,427 million
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingWhether applicable Yes / Subject person Securities analysts and institutional investors
Issued Shares at Period-End63,000,000 shares
Treasury Shares at Period-End2,774,693 shares
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥811,638 million (YoY +0.5%) |
| Operating profit | ¥32,894 million (YoY -17.9%) |
| Ordinary income | ¥28,873 million (YoY -12.1%) |
| Profit attributable to owners of the parent | ¥30,977 million (YoY +22.4%) |
| Net income per share | ¥501.26 |
| Operating Margin | 4.1% |
| Equity ratio | End of the current fiscal period 52.0% / End of previous period 51.2% |
| Total assets | ¥959,154 million |
| Net assets | ¥521,669 million |
| Cash flows from operating activities | ¥50,118 million |
| Cash flows from investing activities | ¥-26,097 million |
| Cash flows from financing activities | ¥-19,988 million |
| Cash and cash equivalents at end of period | ¥48,935 million |
| Full-year earnings forecast | Net Sales ¥820,000 million (YoY +1.0%) / Operating profit ¥36,000 million (YoY +9.4%) / Ordinary income ¥32,000 million (YoY +10.8%) / Net income ¥31,500 million (YoY +1.7%) |
| Annual Dividend Forecast | ¥160 → ¥210（+31.3%） |
| Payout ratio | Fiscal year ending March 2026 31.9% / Forecast for the fiscal year ending March 2027 40.2% |
| Shareholder Return Policy | For fiscal 2025 through fiscal 2027, the Company will maintain or increase dividends on the premise that it maintains financial soundness, following a progressive dividend policy. For the next fiscal year, the consolidated dividend payout ratio is expected to be approximately 40%. |
| Segment revenue | Material Solutions Unit ¥327,235 million, Quality of Life Solutions Unit ¥194,340 million, Health Care Solutions Unit ¥82,975 million, Nutrition Solutions Unit ¥205,977 million |
| Segment profit | Material Solutions Unit ¥24,928 million, Quality of Life Solutions Unit ¥17,954 million, Health Care Solutions Unit ¥14,840 million, Nutrition Solutions Unit ¥13,712 million |
| Regional sales | Fiscal year ending March 2026 ¥447,982 million, ¥163,276 million, ¥74,469 million, ¥83,871 million, ¥42,039 million / Fiscal year ended March 2025 ¥440,431 million, ¥170,313 million, ¥77,101 million, ¥83,303 million, ¥36,051 million |
| Depreciation and amortization | ¥47,427 million |
| Impairment loss | ¥2,404 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of investment securities ¥22,714 million, Subsidy Income ¥2,548 million, Gain on bargain purchase ¥273 million / Extraordinary loss Litigation-Related Costs ¥897 million, Business restructuring loss ¥701 million, Product Warranty Costs ¥2,502 million, Losses from natural disasters ¥594 million, Loss on reduction of fixed assets ¥1,248 million, Provision for special reserve for deferred gain on replacement assets ¥1,300 million, Impairment Losses ¥2,404 million |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 companies / Excluded 0 companies / Company name Not disclosed |
| Material subsequent events | Not applicable. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Securities analysts and institutional investors |
| Issued Shares at Period-End | 63,000,000 shares |
| Treasury Shares at Period-End | 2,774,693 shares |
| Factors Behind Changes in Business Performance | Material posted lower revenue and income due to weak market conditions in Asia and weak demand in the U.S. residential and construction markets. QOL posted higher revenue but lower income due to higher raw material costs. Health Care posted higher revenue and income due to strong growth in Medical. Nutrition posted higher revenue and income due to strong performance in Supplement and improved profitability in Foods. |
Items this document does not state (2)
Revision to Earnings ForecastOrders received and order backlog
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The factors cited include the slowdown in the global economy, uncertainty over supplies of crude oil, naphtha and petrochemical feedstocks due to the situation in the Middle East, weak demand for Material, and the impact of higher raw material costs in QOL. Meanwhile, higher revenue and income in Health Care, driven by expanded sales of Medical, as well as higher revenue and income in Nutrition, supported by strong performance in Supplement and improved profitability in Foods, drove overall results.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.